Is there a role for immunotherapy in Hodgkin’s disease?

To date, most patients with Hodgkin’s lymphoma (HL) can be cured with chemotherapy, radiotherapy or combined modality treatment. However, current treatment is associated with severe side effects and late toxicities such as infertility, cardiovascular damage and secondary malignancies. Moreover, a fraction of patients suffers from refractory disease and cannot be cured with current approaches including high dose chemotherapy and stem cell transplant.